This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Bausch Health Gets 'Positive' Court Ruling on Xifaxan With Market Odds of Bausch + Lomb Distribution at 32%, RBC Says MT
RBC Notes "Positive" Appellate Court Ruling For Bausch Health, But Thinks Market Assigning ~32% BLCO Distribution Odds MT
TSX ends flat as gold stocks drop, mood cautious ahead of rate decision RE
Bausch Health Up Near 0.4% In US Premarket After Announcing Patent Lawsuit Against Amneal Pharmaceuticals MT
North American Morning Briefing : Inflation Data, -2- DJ
Amneal Pharma Gets FDA Nod for Infection Fighting Drug Combination DJ
Amneal Pharmaceuticals Receives FDA Approval for Ear Infection Treatment MT
Amneal Pharmaceuticals, Inc Receives U.S. FDA Approval for Ciprofloxacin and Dexamethasone Otic Suspension CI
Transcript : Amneal Pharmaceuticals, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 08:30 AM
Goldman Sachs Adjusts Price Target on Amneal Pharmaceuticals to $6.25 From $5.50, Maintains Buy Rating MT
Sector Update: Health Care Stocks Edge Higher Premarket Friday MT
Sector Update: Health Care MT
Transcript : Amneal Pharmaceuticals, Inc., Q4 2023 Earnings Call, Mar 01, 2024
Exchange-Traded Funds Higher, Equity Futures Lower Pre-Bell Friday as Traders Turn Cautious After Major US Data Releases MT
Top Premarket Gainers MT
Stock Futures Decrease Pre-Bell as Earnings Season Winds Down; Asia, Europe Fall MT
Amneal Pharmaceuticals' Q4 Adjusted Earnings Decline, Revenue Increases; Sets 2024 Guidance; Shares Rise MT
Amneal Pharmaceuticals, Inc. Provides Earnings Guidance for the Full Year 2024 CI
(AMRX) AMNEAL PHARMACEUTICALS Forecasts Fiscal Year 2024 EPS Range $0.53 - $0.63 MT
Earnings Flash (AMRX) AMNEAL PHARMACEUTICALS Reports Q4 Revenue $617M, vs. Street Est of $634.9M MT
Earnings Flash (AMRX) AMNEAL PHARMACEUTICALS Posts Q4 EPS $0.14, vs. Street Est of $0.09 MT
Amneal Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Amneal Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 CI
Amneal Pharmaceuticals Licenses Parkinson's Drug to Zambon Biotech in EU MT
Amneal, Zambon Sign European Licensing Deal for Parkinson’s Treatment Candidate MT
Chart Amneal Pharmaceuticals, Inc.
More charts
Amneal Pharmaceuticals, Inc., is a fully integrated global essential medicine company. The Company is engaged in the development, manufacturing, and distribution of a diverse portfolio of approximately 270 pharmaceutical products, primarily within the United States. The Company’s Generics segment develops, manufactures and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products and transdermal across a broad range of therapeutic categories. The Company's Specialty segment’s portfolio includes central nervous system disorders (Parkinson’s disease, spasticity, migraine), endocrinology (hypothyroidism), and other therapeutic areas. The Company’s AvKARE segment provides pharmaceuticals, medical and surgical products, and services to government, retail, and institutional markets.
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
5.54 USD
Average target price
7.312 USD
Spread / Average Target
+31.99%
Consensus
  1. Stock Market
  2. Equities
  3. AMRX Stock
  4. News Amneal Pharmaceuticals, Inc.
  5. Goldman Sachs Adjusts Amneal Pharmaceuticals Price Target to $4.50 From $6, Maintains Buy Rating